Oruka Therapeutics (ORKA) risk factors, FY2024 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights

Risks Related to Clinical Development, Regulatory Approval and Commercialization

1. 02We face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates
2. 03Our product candidates may fail in development or suffer delays. We depend on the successful initiation and completion of clinical trials for our product candidates to advance our product development plans
3. 04We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our clinical trials of such programs may not be successful
4. 05If we do not achieve our projected development goals in the time frames we announce and expect, the development and potential commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our stock price may decline
5. 06Any drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks
6. 07Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value
7. 08If we encounter difficulties enrolling participants in our current and future clinical trials, our clinical development activities could be delayed or otherwise adversely affected. We depend on the successful completion of clinical trials for our product candidates
8. 09Preliminary, “topline” or interim data from our clinical trials may change as more participant data becomes available and are subject to audit and verification procedures, and should be viewed with caution until the final data are available
9. 10We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success
10. 11Any approved products resulting from our programs may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products
11. 12Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue

Risks Related to Government Regulation

1. 13We may not be able to meet requirements for the chemistry, manufacturing and control of our programs
2. 14Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated
3. 15We may face difficulties from legislative or regulatory reform measures
4. 16Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules, which could expose us to penalties
5. 17Even if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, we may not be able to offer such product candidates at competitive prices, which would seriously harm our business
6. 18Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any

Risks Related to Our Intellectual Property

1. 19Our ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage
2. 20We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and in-licenses
3. 21We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products
4. 22We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
5. 23Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
6. 24Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 25We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
8. 26We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
9. 27Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time
10. 28Our technology licensed from various third parties may be subject to retained rights

Risks Related to Our Reliance on Third Parties

1. 29We currently rely on our licensing arrangements with Paragon through the License Agreements for a substantial portion of our in-licenses

Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

1. 30In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth
2. 31We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
3. 32Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
4. 33Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all
5. 34Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
6. 35Our hybrid-remote workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations
7. 36If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
8. 37We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition
9. 38We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions
10. 39We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments
11. 40We may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and our insurance may not cover all damages from such claims
12. 41Litigation costs and the outcome of litigation could have a material adverse effect on our business
13. 42Our business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health crises, political crises, geopolitical events or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition

Risks Related to Owning Our Stock

1. 43The market price of our common stock has been, and may continue to be volatile
2. 44Our certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult and may prevent attempts by our stockholders to replace or remove management
3. 45Future sales of shares by existing stockholders could cause our stock price to decline
4. 46We do not anticipate that we will pay any cash dividends in the foreseeable future
5. 47Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
6. 48If equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our market, our stock price and trading volume could decline